Contact MENU

News

ScienceDirect: “Treatment of corneal chemical alkali burns with a crosslinked hyaluronic acid film”

The severe and caustic nature of alkali chemical burns affecting the eye often leads to permanent ocular injury and resulting vision loss. Treatment options are limited, particularly as the topical...

Dr. Paul Karpecki’s article in Ocular Surface Review, “HA: No Laughing Matter”

In this article, Dr. Paul Karpecki takes a closer look at the various hyaluronic acid (HA)-based products optometrists currently have access to and the future role of HA-based therapies in...

EyeGate Poster on Crosslinked Hyaluronic Acid (CMHA-S), Ocular Bandage Gel-based Delivery of Small Molecules

Corneal ulcers are an ocular emergency and a leading cause of blindness globally. The treatment regimen usually requires hourly (or in some cases, even more frequent) round-the-clock administration of topical...

EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel

Responses to three of the four outstanding action items submitted; Response to Fourth action item Expected in the Second Quarter of 2018 with Potential to start clinical study in the...

EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

WALTHAM, Mass., May 16, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders...

EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

WALTHAM, Mass., May. 11, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders...

EyeGate Announces Completion of $11.25 Million Public Offering

WALTHAM, Mass., April 17, 2018 -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders...

EyeGate Announces $11.25 Million Public Offering

WALTHAM, Mass., April 13, 2018 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of...

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Others